ClinicalTrials.gg

Program

milvexian

Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.

Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.

Furthest: phase 3, since Dec 20, 201625 company-led studies, 2 open or runningCo-development: Bristol Myers Squibb and Janssen (Johnson & Johnson), Apr 2018Next primary completion: Dec 8, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb140 open or runningphase 2since Dec 20, 2016Nov 17, 2015none ahead
Johnson & Johnson112 open or runningphase 3since Jan 19, 2023Mar 25, 2019Dec 8, 2026phase 3 · NCT05757869
  • Named in Bristol-Myers Squibb’s own pipeline as milvexian, phase 3, as of Oct 29, 2026 (source).
  • Named in Johnson & Johnson’s own pipeline as milvexian, phase 3, as of Oct 13, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 17, 2015.

  1. Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
  2. Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
  3. Nov 13, 2018Phase 2 study in Ischemic StrokeBristol-Myers Squibb · NCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
  4. Mar 25, 2019Johnson & Johnson’s first study: phase 2 study in Arthroplasty, Replacement, KneeNew to Johnson & JohnsonJohnson & Johnson · NCT03891524 · 1,242 enrolled · United States, Argentina, Belgium and more
  5. May 2, 2019Phase 1 study in ThrombosisBristol-Myers Squibb · NCT03939702 · 9 enrolled · United States
  6. Dec 18, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04206488 · 30 enrolled · Belgium
  7. Jan 8, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04223349 · 66 enrolled · United States
  8. May 12, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04388501 · 23 enrolled · Belgium
  9. Jun 25, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04448964 · 24 enrolled · Belgium
  10. Sep 11, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04569695 · 40 enrolled · China
  11. Apr 12, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04844424 · 115 enrolled · United States
  12. Jul 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04965389 · 17 enrolled · United Kingdom
  13. Jan 19, 2023Phase 3 study in Ischemic StrokeJohnson & Johnson · NCT05702034 · 12,523 enrolled · United States, Argentina, Australia and more
  14. Jan 23, 2023Phase 1 study in Healthy FemaleJohnson & Johnson · NCT05706753 · 20 enrolled · Belgium
  15. Feb 23, 20232 phase 3 studiesJohnson & Johnson · NCT05754957, NCT05757869

Ahead

  1. Dec 8, 2026Primary completion: phase 3 study in Atrial FibrillationJohnson & Johnson · NCT05757869

TargetBeta

“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study

Other programs on F11

ProgramCompanyFurthest phaseStudies
abelacimabanthos-therapeutics-incphase 38
SHR-2004Jiangsu HengRui Medicinephase 35

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05757869Atrial Fibrillation · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonDec 8, 202620,284
NCT05754957Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedJohnson & JohnsonFeb 6, 202614,194
NCT05706753Healthy Female · Belgium1CompletedJohnson & JohnsonJul 20, 202320
NCT05702034Ischemic Stroke · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonOct 15, 202612,523
NCT04965389Healthy Volunteers · United Kingdom1CompletedBristol-Myers SquibbAug 22, 202117
NCT04844424Healthy · United States1CompletedJohnson & JohnsonMay 6, 2022115
NCT04569695Healthy · China1CompletedJohnson & JohnsonDec 4, 202140
NCT04448964Healthy · Belgium1CompletedJohnson & JohnsonNov 14, 202024
NCT04388501Healthy · Belgium1CompletedJohnson & JohnsonOct 25, 202123
NCT04223349Healthy · United States1CompletedJohnson & JohnsonApr 8, 202066
NCT04206488Healthy · Belgium1CompletedJohnson & JohnsonJun 9, 202130
NCT03939702Thrombosis · United States1CompletedBristol-Myers SquibbJul 11, 20199
NCT03891524Arthroplasty, Replacement, Knee · United States, Argentina, Belgium and more2CompletedJohnson & JohnsonApr 6, 20211,242
NCT03766581Ischemic Stroke · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbMar 31, 20222,366
NCT03698513Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 2019113
NCT03362437Thrombosis · United Kingdom1CompletedBristol-Myers SquibbDec 28, 201712
NCT03341390Stroke · United States1CompletedBristol-Myers SquibbNov 16, 201720
NCT03224260Thrombosis · United States1CompletedBristol-Myers SquibbNov 7, 201733
NCT03196206Thrombosis · United States1CompletedBristol-Myers SquibbMar 4, 201824
NCT03000673Antithrombotic · United States2CompletedBristol-Myers SquibbOct 23, 201732
NCT02982707Thrombosis · United States1CompletedBristol-Myers SquibbSep 28, 201826
NCT02959060Thrombosis1CompletedBristol-Myers SquibbDec 201616
NCT02902679Thrombosis · United States1CompletedBristol-Myers SquibbJun 20176
NCT02807909Thrombosis1CompletedBristol-Myers SquibbAug 201628
NCT02608970Thrombosis · Belgium1CompletedBristol-Myers SquibbJul 23, 2017104

How it is read

Names in the registry

  • “BMS-986177”, 14 entries
  • “Milvexian”, 6 entries
  • “JNJ-70033093”, 4 entries
  • “JNJ-70033093 25 mg”, 1 entry
  • “JNJ-70033093 50 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.